TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER (TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER).
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids, electrolytes, and calories (as dextrose). Amino acids are used for protein synthesis, and electrolytes maintain acid-base balance and osmotic pressure.
| Metabolism | Amino acids are metabolized via deamination, transamination, and urea cycle in the liver. Dextrose is metabolized via glycolysis and oxidative phosphorylation. Electrolytes are not metabolized. |
| Excretion | Renal: >95% of infused amino acids and electrolytes are excreted unchanged or as metabolites. Biliary/fecal: <5%. |
| Half-life | Not applicable as a fixed half-life; amino acids have rapid plasma clearance (t1/2 of 10-30 minutes for individual amino acids). Clinical context: Continuous infusion maintains steady state. |
| Protein binding | Minimal for amino acids (<10% bound to albumin); electrolytes are not protein-bound. |
| Volume of Distribution | Amino acids: 0.3-0.5 L/kg (total body water). Electrolytes: Na+ 0.6 L/kg, K+ 4 L/kg, Mg2+ 0.5 L/kg, Cl- 0.3 L/kg, acetate<0.1 L/kg. |
| Bioavailability | IV: 100%. Not administered by other routes. |
| Onset of Action | IV infusion: Immediate for plasma amino acid levels and electrolyte correction; clinical effects (e.g., protein synthesis) occur within hours of administration. |
| Duration of Action | Duration depends on infusion rate; effects persist during continuous infusion. After cessation, plasma levels decline rapidly (minutes to hours). |
| Molecular Weight | 96.09 |
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour, adjusted to meet metabolic needs. Typical adult daily dose: 0.8-1.5 g amino acids/kg/day, equivalent to 23-43 mL/kg/day of TRAVASOL 3.5%.
| Dosage form | INJECTABLE |
| Renal impairment | In acute kidney injury or chronic kidney disease with GFR <30 mL/min/1.73 m², restrict protein intake to 0.6-0.8 g/kg/day; monitor electrolytes closely. For GFR 30-60 mL/min/1.73 m², consider reducing dose to 0.8-1.0 g/kg/day. No specific guidelines for hemodialysis. |
| Liver impairment | In severe hepatic impairment (Child-Pugh C), use with caution; consider branched-chain amino acid enriched solutions; reduce amino acid dose to 0.5-1.0 g/kg/day. Child-Pugh B: no specific adjustment, but monitor for hyperammonemia. |
| Pediatric use | Neonates and infants: 2-3 g amino acids/kg/day; children 1-12 years: 1.5-2 g/kg/day. Administer as continuous IV infusion; adjust based on nitrogen balance and growth. |
| Geriatric use | No specific geriatric adjustment; use lowest effective dose, monitor renal function and fluid status due to increased risk of fluid overload and electrolyte imbalances. Typical dose: 0.8-1.0 g amino acids/kg/day. |
| 1st trimester | TRAVASOL 3.5% is a balanced amino acid solution with electrolytes. Parenteral nutrition may be used in pregnancy when oral/enteral intake is insufficient. No specific teratogenicity is reported for amino acid solutions. Use only if clearly needed. Risk of electrolyte imbalances and fluid overload. |
| 2nd trimester | Similar to T1, no specific teratogenicity. Monitor maternal electrolytes, fluid balance, and fetal growth. Use when benefits outweigh risks. |
| 3rd trimester | Amino acid solutions are used in pregnancy for maternal malnutrition. No known fetal harm. Avoid excessive fluid volume and electrolyte disturbances. |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER (TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER).
| Placental transfer | Amino acids cross placenta via active transport. Plasma amino acid levels are regulated; infusion may increase fetal levels but clinical significance unknown. Electrolytes cross freely. |
| Breastfeeding | TRAVASOL 3.5% is likely compatible with breastfeeding. Amino acids and electrolytes are normal milk components. Intravenous administration may transiently alter maternal levels but pose minimal risk to infant. Consider benefit of maternal nutrition. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Amino acid and electrolyte solutions are generally considered low risk for teratogenicity. No specific fetal risks have been identified in animal studies; however, maternal malnutrition or electrolyte imbalances may indirectly affect fetal development. Use during pregnancy only if clearly needed. |
| Fetal Monitoring | Monitor maternal serum electrolytes, acid-base balance, blood glucose, and renal function. In prolonged use, monitor for signs of volume overload or electrolyte imbalances. Fetal monitoring is not specifically required but may be considered if maternal condition warrants. |
| Fertility Effects | No known adverse effects on fertility. Adequate nutrition and electrolyte balance are essential for reproductive function; deficiency states may impair fertility. |
■ FDA Black Box Warning
WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are at greater risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
| Serious Effects |
Severe electrolyte disorders (e.g., hyperkalemia, hypercalcemia)Severe fluid overload or pulmonary edemaAnuria or oliguriaInborn errors of amino acid metabolism (e.g., maple syrup urine disease)Severe hepatic failure
| Precautions | Use only if solution is clear and container undamaged., Risk of infection and sepsis from catheter use., Monitor fluid and electrolyte balance, blood glucose, liver function, and renal function., Aluminum toxicity risk (see black box warning)., Sulfite-free formulation reduces risk of allergic reactions in sulfite-sensitive patients., Avoid rapid infusion to prevent hyperglycemia and osmotic diuresis. |
| Food/Dietary | No direct food interactions. Parenteral nutrition bypasses the gastrointestinal tract. Avoid oral intake unless clinically indicated. Monitor blood glucose as amino acids may affect glucose metabolism. |
| Clinical Pearls | TRAVASOL 3.5% is a parenteral nutrition solution providing amino acids and electrolytes. Monitor serum electrolytes, renal function, and acid-base balance. Do not administer simultaneously with blood via same IV line due to risk of agglutination. Use inline filter (0.22 micron) during administration. Discontinue if signs of hypersensitivity or infection occur. |
| Patient Advice | This solution is given intravenously to provide nutrition when you cannot eat. · Tell your healthcare provider if you have any allergies, especially to sulfites (this product is sulfite-free). · Inform your provider if you experience fever, chills, redness at infusion site, or difficulty breathing. · Regular blood tests will be done to monitor your electrolytes and kidney function. · Do not adjust the infusion rate yourself; it is controlled by the healthcare team. |
Loading safety data…